Kidney Transplant Recipients Develop Nasal Mucosal Antibodies to SARS‐CoV‐2 With ACE2‐Inhibiting Activity Following mRNA Vaccination
Transplant Infectious Disease · 2026-07 · 28 (4)
DOI: 10.1111/tid.70230 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant Infectious Disease, online erschienen am 07.05.2026. Verfasst von Vera J C H Koomen und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Radboud University Medical Center Nijmegen, Nijmegen, the Netherlands. Hauptthemen laut MEDLINE: Kidney Transplantation, Angiotensin-Converting Enzyme 2, Nasal Mucosa, SARS-CoV-2. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Less than 60% of kidney transplant recipients (KTRs) become IgG seropositive for the viral spike (S) antigen following two COVID‐19 vaccine doses, with a third dose increasing these numbers further. Mucosal antibodies play a critical role in protection against SARS‐CoV‐2 (re)infection; however, the presence and functionality of these antibodies after vaccination have not been well‐studied in high‐risk groups with reduced vaccine immunogenicity.
Methods
We assessed the concentration of ancestral S‐specific antibodies in the nasal mucosa and in serum as well as their capacity to neutralize binding of the receptor‐binding domain (RBD) to the ACE2 receptor in KTRs after two, three, and/or four vaccinations, compared with an age‐matched control group after two vaccine doses.
Results
KTRs showed an increase in nasal and serum S‐specific IgG and S‐specific IgA geometric mean concentrations (GMCs) as well as ACE2 binding inhibition at 28 days after both two‐dose and additional vaccinations compared to baseline, although postvaccination GMCs remained lower than in the control group. We observed a high correlation between nasal and serum antibody levels ( r S > 0.63) and ACE2 inhibiting capacity ( r S > 0.65). Furthermore, nasal S‐specific IgG, and to a lesser extent IgA, was correlated with nasal ACE2 binding inhibition ( r S > 0.64 and 0.5).
Conclusions
KTRs develop nasal mucosal antibodies, which are able to inhibit binding to ACE2 after COVID‐19 vaccination, but at a lower concentration than controls. Mucosal sampling provides an accessible and minimally invasive addition to measuring serum antibodies for monitoring the response to vaccination at a population level. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Radboud University Medical Center Nijmegen, Nijmegen, the Netherlands.
- Department of Laboratory Medicine, Laboratory of Medical Immunology, Radboud University Medical Center Nijmegen, Nijmegen, the Netherlands.
- Division of Nephrology, Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
- Department of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
- Renal Transplant Unit, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
- Department of Internal Medicine, Nephrology and Transplantation, Erasmus MC Transplant Institute, Erasmus Medical Center, Rotterdam, the Netherlands.
ORCID-Profile: Vera J C H Koomen, A Lianne Messchendorp, Renate G van der Molen, Luuk B Hilbrands
Zitieren
APA
Koomen, V. J. C. H., van der Gaast-deJongh, C. E., van Opzeeland, F., Philipsen, R., Baas, M. C., Messchendorp, A. L., Bemelman, F. J., Kho, M. M. L., Baan, C. C., van Baarle, D., Sanders, J. F., van Binnendijk, R., den Hartog, G., Gansevoort, R. T., van der Molen, R. G., Hilbrands, L. B., & Diavatopoulos, D. A. (2026). Kidney Transplant Recipients Develop Nasal Mucosal Antibodies to SARS‐CoV‐2 With ACE2‐Inhibiting Activity Following mRNA Vaccination. Transplant Infectious Disease, 28(4). https://doi.org/10.1111/tid.70230
Vancouver
Koomen VJCH, van der Gaast-deJongh CE, van Opzeeland F, Philipsen R, Baas MC, Messchendorp AL, et al. Kidney Transplant Recipients Develop Nasal Mucosal Antibodies to SARS‐CoV‐2 With ACE2‐Inhibiting Activity Following mRNA Vaccination. Transplant Infectious Disease. 2026;28(4). doi:10.1111/tid.70230
BibTeX
@article{Koomen2026,
author = {Koomen, Vera J C H and van der Gaast-deJongh, Christa E and van Opzeeland, Fred and Philipsen, Ria and Baas, Marije C and Messchendorp, A Lianne and Bemelman, Frederike J and Kho, Marcia M L and Baan, Carla C and van Baarle, Debbie and Sanders, Jan-Stephan F and van Binnendijk, Rob and den Hartog, Gerco and Gansevoort, Ron T and van der Molen, Renate G and Hilbrands, Luuk B and Diavatopoulos, Dimitri A},
title = {Kidney Transplant Recipients Develop Nasal Mucosal Antibodies to SARS‐CoV‐2 With ACE2‐Inhibiting Activity Following mRNA Vaccination},
journal = {Transplant Infectious Disease},
year = {2026},
volume = {28},
number = {4},
doi = {10.1111/tid.70230}
}
EUVIMED